Introduction
Renal transplantation is the treatment of choice for end-stage renal failure. Immunosuppression is an obligate necessity for the acceptance of the graft kidney. The standard immunosuppression with the calcineurin inhibitors (CNIs); cyclosporine A (CsA) or tacrolimus (TAC) along with steroids and antiproliferative drugs like mycophenolate mofetil (MMF) have considerably improved the overall success of renal transplantation. However, they also cause chronic deterioration of allograft function and cardiovascular disease, and extended long-term graft survival has not been achieved. 1, 2 Mammalian target of rapamycin (mTOR) inhibitors provide an alternative in cases of long term morbidity of CNIs and also in post-transplant malignancies including post-transplant lymphoproliferative diseases (PTLD). mTOR inhibitors have also shown promising results in liver transplants.
The pharmacology of mTOR inhibition
The mTOR is a protein kinase at the nexus between oncogenic phosphoinositide 3-kinase (PI3K) signaling and critical down-stream pathways that drive tumor growth. mTOR exists in two complexes called mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2) (Fig. 1 ).
In addition to the mTOR catalytic subunit, mTORC1 contains Raptor, mLST8, and PRAS40; mTORC2 also contains mTOR and mLST8 but is defined by the unique regulatory proteins Rictor, mSIN1, and PROTOR. 3, 4 Both mTORC1 and mTORC2 additionally interact with DEPTOR, which inhibits their activities. 5 The prevailing rationale for mTOR-targeted therapy is based on the premise that Akt, a major PI3K effector, activates the rapamycin-sensitive mTORC1 pathway. The mTOR inhibitors possess a mechanism of action that is different from other classes of immunosuppressants: sirolimus (SRL) and everolimus (EVL) engage FKBP12 to create complexes that engage and inhibit the target of rapamycin but cannot inhibit calcineurin (Fig. 2) . Inhibition of the target of rapamycin blocks signal 3 by preventing cytokine receptors from activating the cell cycle. 6 In addition, mTOR inhibitors may promote tolerance through actions on regulatory T-cells and dendritic cells. 7, 8 Nankivell et al. 9 studied protocol biopsies of renal allografts and described arteriolar hyalinosis and glomerulosclerosis developing after a few years of transplant indicating damage from CsA exposure. The 20 years follow up Australian Multicentre CsA Renal Transplant Study 10 found that patients continuing on CsA had an inferior outcome compared to patients who received CsA only for 3 months and were then converted to azathioprine and corticosteroid.
Immunosuppression is an obligate necessity in kidney transplant. However, the standard immunosuppression causes chronic deterioration of allograft function over long term use. Mammalian target of rapamycin (mTOR) inhibitors provide an alternative in such scenario. The mTOR inhibitors engage FKBP12 to create complexes that engage and inhibit the target of rapamycin. Inhibition of the TOR blocks signal 3 by preventing cytokine receptors from activating the cell cycle. mTOR inhibitors are associated with less viral infection and disease in kidney transplants and also beneficial in post-transplant malignancy. There are various strategies of using mTOR inhibitors either as upfront de novo therapy or later on as switch over therapy. They can also be used in cases of complications arising from standard immunosuppression. mTOR inhibitors also have adverse effects which can be managed by dose reduction but may require stoppage in case of serious complications. Surgical issues need to be kept in mind in view of delayed wound healing. mTOR inhibitors add on to the armamentarium of the available immunosuppression and can give excellent results with judicious use. The present review aims to provide updated information regarding the use of these drugs in post-renal transplantation setting.
ß 2016 Indian Society of Organ Transplantation. All rights reserved.
The study suggested that CNI exposure contributed to deteriorating renal function over long term follow up. CNIs causing these late complications have led to the use of alternate regimens which avoid, minimize or withdraw CNI.
Rationale for mTOR inhibitor use in renal transplantation
mTOR inhibitors are effective immunosuppressant agents in renal transplantation either in combination with a CNI or not. The main rationale for using these agents in a CNI-free regimen is to avoid the adverse events particularly chronic nephrotoxicity. Studies suggest that the safest and most effective time to convert is between 1 and 6 months after transplant. Avoidance of CNIs and the use of mTOR inhibitors also confer benefits with respect to the development of malignancy and also some post-transplant infections.
Post-transplant viral disease
mTOR inhibitors are associated with less cytomegalovirus infection and disease in kidney transplants, [11] [12] [13] whether or not anti-viral prophylaxis is used. 14 Rates of BK virus infection have also been shown to be lower with mTOR inhibitors. 15 In a large case series by Kee et al. 16 found that conversion to SRL and reduction in overall immunosuppression allowed resolution of viremia and stabilization of graft function in 63.4% of patients with polyoma virus allograft nephropathy.
Indian data
A retrospective analysis from south India 17 studied the conversion from CNI based to SRL-based immunosuppressive regimen. CNI was switched to SRL between three months to two years post-transplant for graft dysfunction or malignancy. Significant improvement of GFR was noted after initiation of SRL even in patients with an initial low GFR. SRL was beneficial in posttransplant malignancy as a rescue therapy, especially in Kaposi's sarcoma.
Aleya et al. 18 found that 4 patients who used de novo (first month) EVL for delayed graft function (DGF) and 23 patients who did a late switch (six months post-transplant) for CNI toxicity had an improvement in renal function The median creatinine declined by 0.4-1.1 mg/dL in patients who used EVL for DGF and by 0.2-1.5 mg/dL in late switch patients after a period of six months. The 4 patients who used EVL in the first month had good wound healing with no rejections or lymphocele. None of the patients had bone marrow suppression, or dyslipidemia. (Table 1) 
Options of mTOR inhibitors in renal transplants

CNI free, mTOR inhibitor based immunosuppression upfront
There are conflicting results in a CNI-free, mTOR inhibitor based immunosuppression. The ORION study was a three-arm randomized controlled trial in which patients who received SRL, mycophenolate mofetil (MMF), steroid and basiliximab had a higher rate of acute rejection at 6 months compared with patients receiving a TAC based regimen. 19 The Symphony study 20 which had four arms showed that low dose TAC had improved renal function, graft survival, and acute rejection rates compared with SRL based regimens. A 2011 meta-analysis assessing outcomes associated with reducing CNI exposure from the time of transplantation found that there was no difference in acute rejection rates with mTOR inhibitors and MMF in combination compared with CNI-based regimens (16 studies, n = 2688). 21 A Cochrane review evaluated mTOR inhibitors vs. CNI in de novo renal transplant patients showing that by one year post-transplant, the mTOR inhibitor group had lower risk of acute rejection and higher GFR. 22 Hamdy et al., 23 and Larson et al., 24 showed that a CNI-free regimen using SRL, MMF, prednisolone are safe and efficacious among low to moderate immunologic risk renal transplant recipients even after a long term follow-up of five years. And produce similar acute rejection rates, graft survival, and renal function one to two year after transplantation compared with TAC-MMF-prednisolone.
De novo mTOR inhibitor based CNI-free immunosuppression can be used in low immunological risk and prior malignancy patients. but should also be avoided in those who have native kidney diseases associated with heavy proteinuria, prone to recurrence after transplant. 25 
Upfront mTOR inhibitor-based immunosuppression in addition to low dose CNI
CRADUS09 study demonstrated that reduction in TAC exposure in the presence of EVL, steroids, and basiliximab induction results in good efficacy in de novo renal transplant recipients with very well-preserved renal function. 26 Similar results were seen in the ASSET study where very low-exposure TAC (TAC targeted to C 0 1.5-3.0 ng/mL) EVL (C 0 -h 3-8 ng/mL) + steroids + basiliximab induction had clinically better renal function, with a higher calculated GFR at 12 months without compromising efficacy and a lower incidence of post-transplant diabetes. 27 
Convert to mTOR inhibitors based immunosuppression and stopping CNI
Conversion from CNI-based to mTOR inhibitors-based immunosuppression can be early (between two and six months) or late (after six months) post-transplant. Late conversions are usually reactive because of CNI-related nephrotoxicity or because of development of chronic allograft dysfunction. The Rapamune Maintenance Regimen (RMR) study first described the beneficial effect of long-term CNI free mTOR inhibitor therapy in renal transplantation. 28 Patients were randomized at 3 months to either continue a regimen of SRL, CsA and steroids, or to have CsA withdrawn with an increase in the concentration of the targeted dose of SRL. In spite of having numerically greater numbers of rejections in the 3 months after randomization, at 4 years the patients in whom CsA was withdrawn had superior renal function and graft survival compared with those who continued the combination of CsA and SRL. Protocol biopsies performed at 36 months also showed less chronic allograft nephropathy in the CsA withdrawal group. 29 In vitro studies suggest that the combination of a CNI and an mTOR inhibitor provide immunological synergy. However, the main limitation of this combination in clinical practice is the enhanced nephrotoxicity of the CNI. EVL based trials with a reduced dose of CsA have shown that efficacy is maintained without any deterioration of renal function in the first two years. 11 This approach allowed a 60% reduction in exposure to the CNI over a 12-month time frame.
A meta-analysis of 22 randomized controlled trials found that compared to CNI-based regimens, conversion to mTOR-inhibitorbased regimens were associated with improved renal function (estimated GFR) at 12 months and this was sustained 5 years posttransplant. When results at 12 months were stratified by time to conversion, early conversion (<12 months post-transplant) was found to result in improved graft function compared with later conversion. 30 Infection rates were similar but edema, proteinuria and hyperlipidemia, was higher for mTOR inhibitors. Intolerance to mTOR inhibitors is seen in up to 25% of patients.
These studies suggest that rejection episodes occur after conversion in about 5-10% of patients. The increased rates of rejection in the SYMPHONY study may possibly be explained by sub-therapeutic dosing of SRL. 20, 31 The CONCEPT study suggests that there is a greater chance of rejection on steroid withdrawal from an mTOR-inhibitor/MMF combination. There was an increase in the rejection rate in the conversion arm but this only occurred after steroids were withdrawn by protocol at 8 months. 12 
Add mTOR inhibitors-based immunosuppression and reducing dose of CNI
The CALLISTO study showed EVL to be effective in renal transplant recipients when the drug is added at around two-month post-transplantation along with low dose CsA. 32 2.5. Potential case scenarios
Renal dysfunction
Studies have addressed both early preemptive conversion (CONCEPT, STN, ERIC, ZEUS) and late preemptive conversion (CONVERT). Studies with earlier conversion have shown greater benefit to renal function. The CONCEPT trial found that conversion at 3 months from CsA to SRL in a regimen of CsA, MMF, steroids and daclizumab leads to a clinically significant improvement in renal function without any detriment to graft or patient survival at 12 months. 12 The Spare-the-Nephron (STN) study from the USA randomized patients on a CNI, MMF and steroid regimen to conversion to a SRL/MMF/steroid regimen 1-6 months after transplantation. 33 At 1 year, the measured GFR in the converted group had significantly improved by 24% compared with 5% in the control. The difference between groups was maintained at 2 years.
The CONVERT study examined conversion from a CNI to SRL, approximately 3 years after transplantation. Two years after conversion, renal function improved insignificantly in patients with good transplant function (glomerular filtration rate (GFR) >40 mL/ min). Inferior outcomes were seen in those with poorer function or significant proteinuria. 34 Conversion to mTOR inhibitors has been demonstrated to be effective in improving renal function in CNI treated renal transplant recipients with graft dysfunction 35 ; however proteinuric patients or those with severe histological damage may not derive comparable benefit. 36 DGF could be a potential indication where continuation of CNI is not desirable and ATG may not be cost effective in financially constrained settings; but there are conflicting reports showing delay in recovery from DGF 37 where cadaveric renal recipients receiving SRL based regimen had higher DGF (39%) as compared to CsA based regimen (34.8%).
Malignancy
Patients treated with SRL have a lower rate of post-transplant malignancy than those with CNI-based regimens. Guba et al., 38 suggested that different immunosuppressants confer differing risks of malignancy development. The effect of SRL on cell proliferation and neovascularization helps in preventing the development of malignancy. 38 SRL based regimens are less immunosuppressive that reduces the risk of cancer. 39 United Network for Organ Sharing registry data have also showed a lower Table 1 Options of mTOR inhibitors in renal transplants.
1. CNI free, mTOR inhibitor based immunosuppression upfront 2. Upfront mTOR inhibitor-based immunosuppression in addition to low dose CNI 3. Convert to mTOR inhibitors based immunosuppression and stopping CNI as a preventive strategy or as a response to complications 4. Add mTOR inhibitors-based immunosuppression and reducing dose of CNI to prevent or tackle complications incidence of both skin and solid organ malignancy in patients taking mTOR inhibitors (alone or in combination with CNIs) compared with patients on a CNI-based regimen. 40 Although they were not designed to evaluate cancer outcomes, the RMR study, 41 the CONVERT study 42 and the CONCEPT study 43 all showed a reduced rate of malignancy development after conversion from a CNI to an mTOR inhibitor. The 407 skin cancer study 44 was a randomized controlled trial that assessed cancer development after conversion from a CNI to an mTOR inhibitor. The intention to treat population showed the rate of non-melanoma skin cancer development was 2.48 per patient-year in the group continuing CNIs compared with 1.31 in the group converted to SRL (P = 0.022).
In the TUMORAPA study, SRL demonstrated a significant antitumoral effect at 2 years with a decreased risk of new squamous cell carcinoma and longer time to development of new lesions. 45 mTOR inhibitors have anti-cancer properties with promising results in the treatment of nontransplant patients with B-cell lymphomas like relapsed mantle cell lymphoma. 46 Campistol et al. 47 showed complete reversal of cutaneous Kaposi's sarcoma after conversion from CsA to SRL. However it is not replicated in transplant patients with disseminated malignancy. Conversion from CNI to SRL has been successful in control of EBV-driven posttransplant malignancy. 48 Benefit may be obtained from converting patients who have multiple non-melanoma skin malignancies. 49 Data suggest that mTOR inhibitors may assist with the management of PTLD following renal transplant. 50 
To reduce the cardiovascular risk factors
Cardiovascular disease is the leading cause of death with a functioning graft. Reducing cardiovascular risk factors will have an impact on long-term patient survival. In the RMR study at 36 months, mean arterial blood pressure was significantly lower in the group where CsA was eliminated and patients were maintained on SRL and steroids alone. 51 
To reduce CNI-related adverse effects
Thrombotic microangiopathy occurs as an adverse effect to CNIs and may warrant substitution with mTOR inhibitors. 52 However there is a risk of potentiation of CNI-induced endothelial damage with contiguous CNI then SRL use. 53 CNI-based immunosuppressive regimens are sometimes associated with neurotoxicity, such as tremors and seizures, which is not dose related, and may be difficult to control with antiepileptic medications. Moreover, cosmetic side effects seen in patients on CNIs, such as hirsutism and gum hypertrophy with CsA and alopecia with TAC, may warrant conversion to mTOR inhibitors.
2.6. Adverse effects 2.6.1. Proteinuria mTOR inhibitors may tend to cause proteinuria. 54, 55 CONVERT study 34 showed that baseline proteinuria and the degree of renal injury before conversion were poor prognostic indicators. Diabetes kidney failure also predict the development of proteinuria with use of mTOR inhibitors. However head to head comparison of mTOR inhibitors to CNI do not generally show a clinically significant association of mTOR inhibitors with proteinuria. 56 Proteinuria, when it develops is usually mild in appropriately selected patients. It is easily managed with angiotensin-converting enzyme inhibitors (ACEis) or angiotensin receptor blockers (ARBs) and does not require discontinuation of mTOR inhibitors. It should be noted that combined therapy with mTOR inhibitors and ACEI in kidney transplant recipients can result in angioedema. 57 Proteinuria can be managed by treatment of hypertension, salt restriction and the use of diuretics. If proteinuria is not adequately controlled then shifting to alternative immunosuppressant is necessary.
Pneumonitis
Interstitial pneumonitis has been reported in association with mTOR inhibitors therapy (about 10% in various series). 58, 59 Patients are symptomatic with dry cough and dyspnea on exertion. Imaging usually reveals bilateral patchy or diffuse alveolo-interstitial infiltrates. The diagnosis needs to be made after excluding other infectious causes (PCP, CMV, bacterial, TB or fungal causes). Higher trough levels of mTOR inhibitors (>12 ng/mL), patients with greater renal insufficiency, and patients with late conversion, older patients, and use of loading dose have increased risk. Pneumonitis may resolve on reducing the dose of mTOR inhibitors, but cessation of the mTOR inhibitors may be required where the condition persists. The associated clinical and radiologic improvement after its cessation suggests a causal relationship. Resolution of SRL-induced pneumonitis have been reported after conversion to EVL. 60,61
Dyslipidemia
The incidence of dyslipidemia is significantly higher with mTOR inhibitors therapy than with other immunosuppressants. 62 The exact mechanism is not fully understood. Dyslipidemia should be managed in the same way as it is for nontransplant patients at high risk for cardiovascular disease.
Bone marrow suppression
The bone marrow suppression by mTOR inhibitors is dose and concentration dependent, 63 and megakaryocytes are more susceptible than leukocytes. The concurrent use of other bone marrow suppressants such as MMF, valganciclovir or infections (parvovirus B19, CMV) should be ruled out. Management entails adjustment of mTOR inhibitors dose and blood levels.
2.6.5. Other complications 2.6.5.1. Pneumocystis carinii. PCP prophylaxis is highly recommended for patients on mTOR inhibitors. 64 Causal relationship is still not established.
2.6.5.2. Oral ulcers. Oral ulcers are a common side effect of mTOR inhibitors. 65 Antiproliferative effect of mTOR inhibitors and the effect of mTOR inhibitors on growth factors may be responsible for its occurrence. Mild mucosal and aphthous ulcerations respond to a reduction in dose and conservative measures such as the application of triamcinolone or clobetasol. mTOR inhibitors should be stopped temporarily in severe lesions. In general, mucosal ulcerations disappear within two weeks after mTOR inhibitors discontinuation.
2.6.5.3. Edema. Chronic edema has been reported in 8-62% of transplant recipients on SRL. 66 The mechanism involves the inhibition of growth of smooth muscle cell and reduction in endothelial growth factor production, which alter local blood pressure and local vascular permeability, facilitating occurrence of the edema. Edema disappears or improves with reduction or stoppage of SRL. Angioedema, mainly on the face, has been reported in 15% of transplant recipients on SRL. 67 2.6.5.4. Diarrhea. Diarrhea occurs in about 1/4th of SRL trials. 68 Diarrhea is reported more frequently in patients given SRL + MMF. The exact mechanism of is not well known but is dose dependent.
Situations requiring mTOR inhibitors adjustment or cessation
Surgical issues
Delayed wound healing has been associated with SRL use. A retrospective review found that wound complications occurred more frequently in renal allograft recipients treated with SRL (43.2%). 69 Studies with EVL have revealed similar results 70 and seem to be dose dependent. In a comparative study from India on 80 renal transplant recipients, use of mTOR inhibitors resulted in significantly higher wound complications compared with that of MMF leading to prolonged hospital stay. However, a retrospective multivariate analysis 71 concluded that the only individual factors associated with an increased risk for wound complications were obesity and DGF; the introduction of MMF and SRL did not result in a significant increase in transplant wound complications. It is advisable that wound healing be complete before conversion to mTOR inhibitors. It is prudent to stop mTOR inhibitors during major surgery. In case of an emergent surgery, the abdominal walls and fascias should be closed with nonabsorbable sutures and they should remain in situ for 14-21 days; the patient should be temporarily converted from mTOR inhibitors to another immunosuppressant until the wound healing is complete.
Lymphoceles
Patients converted to mTOR inhibitors therapy in the early posttransplant setting should have their graft screened for the development of lymphoceles. Lymphoceles may require percutaneous drainage or methods like marsupialisation in clinically significant recurrence.
Tuberculosis
Tuberculosis infections or reactivation can occur among patients receiving SRL-based immunosuppression. 72, 73 In India where tuberculosis is highly prevalent, caution should be exerted in patients administered mTOR inhibitors if unexplained fever or respiratory symptoms develop. John 74 has suggested the possibility that SRL-treated patients will show less fibrosis and more cavitating disease and slow clinical response in a patient immunosuppressed with this drug.
Fertility issues/pregnancy
There are no adequate and well-controlled studies with mTOR inhibitors in pregnant women; however, no structural defects have yet been reported with early pregnancy following SRL exposures. Patients treated with SRL throughout the post-transplant period have a significantly low sperm count and decreased motility as compared to other immunosuppression and may reduce male fertility. 75 
Worsening renal function
SRL has been implicated in the prolongation of DGF 76 and in inhibiting the recovery of acute tubular necrosis. 37 This is most likely due to the drugs antiproliferative action on recovering renal tubular epithelial cells. However, in the ORION study, there was no difference in the rate or duration of DGF when the TAC/MMF arm was compared with the SRL/MMF arm. 19 Reversible factors should be excluded prior to implicating mTOR inhibitors. If acute tubular necrosis develops or renal function deteriorates significantly, temporary cessation of mTOR inhibitors may be necessary.
Hepatitis C
Switching to SRL in renal transplant recipients with hepatitis C virus is safe. 77 On the other hand, there are reports describing SRLrelated hepatotoxicity and an increase in viral load in liver transplant recipients following conversion to SRL from CNI. Activation of the N-Ras-PI3K-Akt-mTOR signaling pathway may contribute not only to cell survival of HCV-infected cells but also to low steady-state levels of HCV replication, both of which may contribute to the establishment of persistent infection. 78 2.8. How to start, maintain, convert from CNI? SRL can be initiated at 2 mg/d for two days followed by a maintenance dose of 1 mg/d. A 25% reduction in CNI dosage can be made in one week followed by a further 25% reduction over the next two weeks. Subsequent reduction of CNI is made after monitoring of SRL levels, which was maintained between 4 and 8 ng/mL In case of EVL the levels are maintained between 3 and 8 ng/mL in de novo and 3-5 ng/mL in most of late switch patients.
The effect of mTOR inhibitors on renal function in patients of liver transplant
In two large retrospective studies in which patients received SRL as de novo therapy, there were reductions in the GFR up to 1 year 79 or up to 5 years after transplant. 80 In contrast, in a third de novo, retrospective (low quality) study, modest improvements in renal function in patients receiving SRL were recorded at both 6 and 12 months after transplant. 81 Few prospective and retrospective studies stratified renal function in liver transplant recipients based on timing of conversions from CNI to SRL. [82] [83] [84] [85] There were significantly higher estimated GFR levels in patients converting at <90 days after transplant compared to those converting after day 90, at 3, 9, and 12 months after conversion. In a study with patients with GFR <50 mL/min, there was a significant increase in measured GFR that persisted for 5 years after conversion in patients who converted to SRL at either 3 months or 1 year after transplant. Conversion at 3 months produced greater improvements in 5-year renal function than conversion at 1 year. In contrast, there was no difference in GFR after SRL conversion at 2 years after transplant, and later conversions at 5 years and 10 years after transplant resulted in a significantly decreased GFR. 85 
Conclusion
mTOR inhibitors are a good alternative immunosuppression in the long run and avoids the long term toxicity of CNIs. De novo or early conversion of mTOR inhibitors have the risk of poor wound healing and needs close observation. They have relatively low nephrotoxicity and are a good alternative in malignancy, viral infections and a failing graft. Monitoring of the drug levels can minimize the adverse effect profile. mTOR inhibitors adds on to the armamentarium of the available immunosuppression and can give excellent results with judicious use.
